Austria’s Apeiron To Attack COVID-19 At Its Entry Point

Phase II Study Starts In Three European Countries

 
• By John Davis
  
Peter Llewellyn-Davies
Apeiron Biologics CEO Peter Llewellyn-Davies • Source: Apeiron Biologics

More from COVID-19

More from Scrip